VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss as well as improvements in waist circumference and waist circumference-to-height ratio (CHECK), in patients with preexisting cardiovascular disease (CVD), overweight or obesity…
